HUMAN RECOMBINANT CB1 RECEPTOR
MULTISCREEN™ MEMBRANE PREPARATION
1 vial (8.15mg/mL), 1, 5, 10mg
Packaging Buffer: 20mM Gly-Gly, 1 mM MgCl2, 25mM Sucrose (pH 7.2)
Expression vector containing full-length human CB1 cDNA (GenBank Accession Number: NM_016083) with FLAG tag sequence at N-terminus.
Liquid nitrogen upon receiving. Avoid repeated freeze-thaw.
Background: Cannabinoid Receptor 1, CNR1 also known as CB1, is involved in cannabinoid induced CNS effects. It acts by inhibiting intracellular adenylate cyclase activity and could be a receptor for anandamide. CNR1 is a potential target for the development of novel therapeutic drugs in the treatment of various conditions, such as pain, feeding disorders, vascular disease, Parkinson’s disease, and other central nerve system disorders.
Figure 1. Receptor expression on cell surface measured by flow cytometry (FACS) using an anti-FLAG antibody. Thin line: parental cells; thick line: receptor-expressing cells.
Gerard, C., C. Mollereau, et al. (1990). “Nucleotide sequence of a human cannabinoid receptor cDNA.” Nucleic Acids Res 18(23): 7142
Mendizabal, V. E. and E. Adler-Graschinsky (2003). “Cannabinoid system as a potential target for drug development in the treatment of cardiovascular disease.” Curr Vasc Pharmacol 1 (3): 301-13